Portal de recerca
MIELOMA MULTIPLE: GRUPOS DE RIESGO BASADOS EN NUEVOS BIOMARCADORES Y EVALUACION DE INTERVENCIONES TERAPEUTICAS CON INTENCION CURATIVA CON TECNICAS PARA EMR DE ALTA SENSIBILIDAD
Dades bàsiques
- Codi Financador:
- PI12/01569
- Any inicial:
- 2013
- Any final:
- 2015
Objectius del projecte
FAVORABLE
Documents
- No hi ha documents
Participants
-
Javier De La Rubia Comos
Investigador Principal
Grups d'Investigació
-
Hematología y Hemoterapia
Investigador Principal
Javier De La Rubia Comos
Finançadors
Resultats del Projecte
Aplicación de técnicas de identificación de poblaciones celulares por citometría de flujo
LOURDES CORDÓN GALLEGO, Sempere Talens, A., Cuñat Estellés, P.
Capítulo de un Libro. 2014
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML
Perez Miguez, Carlos; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2024-201407. 2024
A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study.
Rios-Tamayo, Rafael; (...); Mateos, Maria Victoria
Article. 10.1080/16078454.2023.2178997. 2023
A global study for acute myeloid leukemia with RARG rearrangement.
Zhu, Hong-Hu; (...); Chen, Su-Ning
Article. 10.1182/bloodadvances.2022008364. 2023
A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control (vol 27, pg 2112, 2013)
Paiva, B.; (...); Miguel, J. F. San
Article. 10.1038/leu.2013.213. 2013
A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.
Paiva B; (...); Grupo Español de MM
Article. 10.1038/leu.2013.166. 2013
A NEW INTRONIC MUTATION CAUSES AN ABERRANT SPLICING IN THE ANK1 GENE
Liquori, A.; (...); Cervera, J., V
Meeting Abstract. 2018
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis
Cibeira, MT; (...); Blade, J
Article. 10.1111/bjh.13500. 2015
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
Martínez-Cuadrón D; (...); CETLAM and PETHEMA groups
Article. 10.1007/s00277-018-3229-5. 2018
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
Hajek, R; (...); Ludwig, H
Article. 10.1038/leu.2016.176. 2017
A Rare Case of Pure Erythroid Sarcoma in a Pediatric Patient: Case Report and Literature Review.
Manresa, P; (...); Martirena, F
Article. 10.3390/children4120113. 2017
A reproducible strategy for analysis of minimal residual disease measured by Standardized multiparametric flow cytometry in b acute lymphoblastic leukemia
Palao, HS; (...); Lopez, F
Letter. 10.1002/cyto.b.21720. 2019
A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms
Liquori, A; (...); Cervera, J
Article. 10.3390/cancers13081947. 2021
A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): Results of a randomised controlled clinical trial
Meeting Abstract. 2018
Aberrant Alternative Splicing in U2af1/Tet2 Double Mutant Mice Contributes to Major Hematological Phenotypes
Martínez-Valiente C; (...); Sanjuan-Pla A
Article. 10.3390/ijms22136963. 2021
Acute hemolytic reaction by anti-Wra: Case report and review of the hemovigilance database of a tertiary care hospital.
Solves, Pilar; (...); de la Rubia, Javier
Article. 10.1016/j.transci.2021.103342. 2022
Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): Clinical and biological features and comparison with other acute myeloid leukemias with cytogenetic aberrations involving long arm of chromosome 3
Raya JM; (...); Florensa L
Article. 10.1179/1607845415Y.0000000003. 2015
Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene
Review. 10.3390/cancers12030624. 2020
Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene (vol 12, 624, 2020)
Article. 10.3390/cancers13143440. 2021
ADAMTS13 RECOVERY IN ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA AFTER CAPLACIZUMAB THERAPY. THE SPANISH REGISTRY.
Mingot-Castellano, Maria Eva; (...); Pascual Izquierdo, Cristina
Article. 10.1182/blood.2023022725. 2024
Adoptive transfer of ex-vivo expanded SARS-CoV-2-specific Cytotoxic Lymphocytes: a viable strategy for COVID-19 immunosuppressed patients?
Guerreiro M; (...); Piñana JL
Article. 10.1111/tid.13602. 2021
Adverse prognostic impact of complex karyotype (>= 3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)
Genesca, E; (...); Ribera, JM
Article. 10.1016/j.leukres.2021.106612. 2021
Adverse prognostic value of MYBL2 overexpression and association with microRNA-30 family in acute myeloid leukemia patients.
Fuster O; (...); Barragán E
Article. 10.1016/j.leukres.2013.09.015. 2013
Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B- Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study
Bar, Noffar; (...); Costa, Luciano
Meeting Abstract. 10.1182/blood-2023-180013. 2023
Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
Wong, Sandy W.; (...); Costa, Luciano J.
Meeting Abstract. 10.1182/blood-2022-159009. 2022
ALTERED PHENOTYPES OF MATURING NEUTROPHILS IN MDS
Meeting Abstract. 10.1016/S0145-2126(17)30114-5. 2017
Allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma. Impact of disease characteristics, disease status at transplant, and prior number of lines of therapy. Results of retrospective, multicentre Spanish study
De la Rubia, J; (...); Gonzalez, MS
Meeting Abstract. 2019
ALLOGENEIC TRANSPLANTATION OF HEMATOPOIETIC PROGENITORS (T-ALO) IN PATIENTS WITH MULTIPLE MYELOMA (MM). IMPACT OF BIOLOGICAL CHARACTERISTICS TO DIAGNOSIS, TPH DISEASE SITUATION AND TREATMENT LINES. SPANISH MULTICENTRIC RETROSPECTIVE STUDY
Perez, A.; (...); Solano, C.
Meeting Abstract. 2019
Analysis of minimal residual disease in bone marrow by NGF and in peripheral blood by mass spectrometry in newly diagnosed multiple myeloma patients enrolled in the GEM2012MENOS65 clinical trial.
Puig, Noemi; (...); Mateos, Maria-Victoria
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.8010. 2021
Analysis of Peripheral Blood and Bone Marrow Residual Disease Dynamics during Intensive Treatment and Maintenance in Patients with Multiple Myeloma Included in the GEM12MENOS65 and GEM14MAIN Clinical Trials
Puig, Noemi; (...); Victoria Mateos, Maria
Meeting Abstract. 10.1182/blood-2023-184837. 2023
ANALYSIS OF PROGRESSION-FREE SURVIVAL OF AND GLOBAL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA OLDER THAN 65 YEARS CANDIDATES FOR AUTOLOGOUS PERIPHERAL BLOOD TRANSPLANTATION NON-CANDIDATES
Cejalvo, MJ; (...); De la Rubia, J
Meeting Abstract. 2017
ANALYSIS OF RESIDUAL DISEASE IN PERIPHERAL BLOOD BY MEANS OF MASS SPECTROMETRY IN PATIENTS WITH MULTIPLE MYELOMA OF THE GEM 2012 MINUS65. COMPARISON WITH THE IMWG STANDARD RESPONSE AND RESIDUAL DISEASE CRITERIA
Puig, N.; (...); Mateos, M., V
Meeting Abstract. 2021
Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype
Ibanez, M; (...); Cervera, J
Article. 10.1038/s41598-020-61589-9. 2020
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.
Pessoa de Magalhães RJ; (...); Orfao A
Article. 10.3324/haematol.2012.067272. 2013
Analysis of the Possible Persistent Genotoxic Damage in Workers Linked to the Ardystil Syndrome
Montoro, Alegria; (...); Ignacio Villaescusa, Juan
Article. 10.1089/gtmb.2015.0177. 2016
ANALYSIS OF THE PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN ELDERLY PATIENTS (65 YEARS OLD) WITH MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION.
Cejalvo, MJ; (...); De la Rubia J
Meeting Abstract. 2018
Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: does -7/7q- detection by FISH have prognostic value?
Ademà V; (...); Solé F
Article. 10.1016/j.leukres.2012.12.010. 2013
APPLICATION OF THE MASS SEQUENCING FOR THE STUDY OF MUTATIONS, REORDERINGS AND CHANGES IN GENE EXPRESSION IN THE HEMATOLOGICAL MYELOID NEOPLASIAS
Simarro, CS; (...); Gonzalez, EB
Meeting Abstract. 2018
APPROACH TO THE STUDY OF THE ALTERATIONS OF METABOLISM IN THE LMA
Simarro, CS; (...); Gonzalez, EB
Meeting Abstract. 2018
Assemblable 3D biomimetic microenvironment for hMSC osteogenic differentiation
Martins, Luis A.; (...); Gomez-Ribelles, Jose Luis
Article. 10.1088/1748-605X/ad7dc4. 2024
Assessing an improved protocol for plasma microRNA extraction.
Moret I; (...); Beltrán B
Article. 10.1371/journal.pone.0082753. 2013
Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial
Puig, Noemi; (...); Mateis, Maria-Victoria
Meeting Abstract. 10.1182/blood-2021-151557. 2021
Association of Unbalanced Translocation der(1;7) with Germline GATA2 Mutations.
Kozyra, EJ; (...); Wlodarski, MW
Article. 10.1182/blood.2021012781. 2021
Atypical B-Cell Acute Lymphoblastic Leukemia with iAMP21 in the Context of Constitutional Ring Chromosome 21: A Case Report and Review of the Genetic Insights.
Gil, Jose Vicente; (...); Llop, Marta
Article. 10.3390/ijms26010357. 2025
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
Bernard E; (...); Papaemmanuil E
Correction. 10.1038/s41591-021-01253-5. 2021
Autoimmune cytopenias after umbilical cord blood transplantation in adults with hematological malignancies: a single-center experience
Article. 10.1038/bmt.2014.107. 2014
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis
Casanova, B; (...); Coret, F
Article. 10.1007/s10072-017-2933-6. 2017
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries
Diez-Campelo, M; (...); Fenaux, P
Article. 10.1111/bjh.15190. 2018
Baseline circulating myeloid-derived suppressor cells correlate with neutrophil-to-lymphocyte ratio and overall survival in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors
Garcia-Sanchez, J.; (...); Lahoz, A.
Meeting Abstract. 2021
Baseline circulating myeloid-derived suppressor cells subpopulations, neutrophils/lymphocytes ratio, and response to PD-1/PD-L1 inhibitor in non-small cell lung cancer patients.
SAnchez, JosE GarcIa; (...); Lahoz, Agustin
Meeting Abstract. 2020
Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial
Gonzalez-Calle, Veronica; (...); Mateos, Maria-Victoria
Meeting Abstract. 10.1182/blood-2022-162584. 2022
Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-VRd Trial
Gonzalez-Calle, Veronica; (...); Mateos, Maria-Victoria
Meeting Abstract. https://doi.org/10.1182/blood-2022-162584. 2024
Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort
De la Rubia, Javier; (...); Alegre, Adrian
Meeting Abstract. 10.1182/blood-2022-158538. 2022
Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain.
de la Rubia, Javier; (...); Alegre, Adrian
Article. 10.3390/cancers15112964. 2023
Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura
Gomez-Segui, I, Izquierdo, CP, Comos, JD
Review. 10.1080/17474086.2021.1956898. 2021
Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukemia: analysis of 627 patients with isolated 13q deletion
Puiggros, Anna; (...); Espinet, Blanca
Article. 2013
Biomimetic 3D Environment Based on Microgels as a Model for the Generation of Drug Resistance in Multiple Myeloma.
Marin-Paya, Juan Carlos; (...); Gomez Ribelles, Jose Luis
Article. 10.3390/ma14237121. 2021
Biomimetic microspheres for 3D mesenchymal stem cell culture and characterization
Clara-Trujillo, S; (...); Ribelles, JLG
Article. 10.1016/j.colsurfb.2019.01.050. 2019
Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET degradation that can be therapeutically restored in vitro.
Article. 10.3389/fimmu.2023.1171065. 2023
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial
Rosiñol L; (...); Bladé J
Article. 10.1038/leu.2017.35. 2017
Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma
Blanes M; (...); de la Rubia J
Article. 10.3109/10428194.2014.922182. 2015
BRAF V600E mutation in adult acute lymphoblastic leukemia.
Alonso CM; (...); Sanz Alonso MA
Letter. 10.3109/10428194.2012.733878. 2013
BUMEL vs MEL-200 prior autologous transplant for patients with newly diagnosed multiple myeloma previously treated with bortezomib, lenalidomide and dexamethasone: final results of a phase 3 trial
Lahuerta Palacios, Juan Jose; (...); Blade, Joan
Meeting Abstract. 2022
Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)
Coppo, Paul; (...); Scully, Marie
Meeting Abstract. 10.1182/blood-2023-179316. 2023
Caplacizumab Treatment in Elderly Patients with iTTP: Updated Experience from the Spanish TTP Registry
Gomez Segui, Ines; (...); De La Rubia, Javier
Meeting Abstract. 10.1182/blood-2023-180970. 2023
Case report of a trichohepatoenteric syndrome due to heterozygous compound of novel mutations in ttc37 gen
Polo, B.; (...); Cervera, J.
Meeting Abstract. 2019
CASE REPORT OF SHAAF-YANG SYNDROME WITH A DE NOVO MUTATION IN MAGEL2 GEN
Pi, G.; (...); Cervera, J.
Meeting Abstract. 2019
Case Report: Partial Uniparental Disomy Unmasks a Novel Recessive Mutation in the LYST Gene in a Patient With a Severe Phenotype of Chediak-Higashi Syndrome.
Boluda-Navarro, Mireia; (...); Cervera, Jose Vicente
Article. 10.3389/fimmu.2021.625591. 2021
CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia
Barragán E; (...); Odero MD
Letter. 10.3324/haematol.2014.118117. 2015
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.
Garces, Juan-Jose; (...); Paiva, Bruno
Article. 10.1200/JCO.21.01365. 2022
Cis-Acting Splicing-Associated Variants Can Redefine the Molecular Signature of Genes Commonly Mutated in Acute Myeloid Leukemia
Morote-Faubel, Mireya; (...); Cervera, Jose
Meeting Abstract. 10.1182/blood-2023-177571. 2023
Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group
Nomdedeu, M; (...); Spanish MDS Group
Article. 10.1016/j.leukres.2017.10.011. 2017
Clinical and biological significance of Y chromosome loss in a series of 2,423 male patients with Myelodysplastic syndromes and Chronic Myelomonocytic Leukemia
Costa, D.; (...); Campo, E.
Meeting Abstract. 2018
Clinical and molecular characterization by next generation sequencing of Spanish patients affected by congenital deficiencies of fibrinogen.
Moret, A; (...); Bonanad, S
Letter. 10.1016/j.thromres.2019.06.015. 2019
CLINICAL AND MOLECULAR CHARACTERIZATION OF PATIENTS WITH THERAPY RELATED MYELOID NEOPLASMS
Calvete, O.; (...); Sole, F.
Meeting Abstract. 10.1016/j.leukres.2023.107176. 2023
Clinical and Molecular Characterization of Patients with Therapy Related Myeloid Neoplasms ( TRMN)
Calvete, Oriol; (...); Kanagal-Shamanna, Rashmi
Meeting Abstract. 10.1182/blood-2023-188701. 2023
CLINICAL APPLICATION OF THE MASSIVE SEQUENCING ADDRESSED IN ACUTE MYELOBLASTIC LEUKEMIA
Garcia, ML; (...); Gonzalez, EB
Meeting Abstract. 2017
Clinical Characteristics and Cardioavscular Events in Patients with Esential Thrombocythemia with < 10% Vs. >= 10% JAK2 V617F Allele Burden
Xicoy, Blanca; (...); Zamora, Lurdes
Meeting Abstract. 10.1182/blood-2019-126980. 2019
Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies
Askari, Elham; (...); Garcia-Sanz, Ramon
Meeting Abstract. 10.1182/blood-2023-189581. 2023
Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial
Puig, Noemi; (...); Mateos, Maria-Victoria
Meeting Abstract. 10.1182/blood-2022-165441. 2022
Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics
Goicoechea, I; (...); Paiva, B
Meeting Abstract. 10.1182/blood-2018-99-113312. 2018
Clinical Significance of Sensitive Flow-MRD Monitoring in Elderly Multiple Myeloma Patients on the Pethema/GEM2010MAS65 Trial
Paiva, Bruno; (...); San Miguel, Jesus F.
Meeting Abstract. 2014
Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics
Alonso, CM; (...); Barragan, E
Article. 10.1016/j.jmoldx.2018.09.009. 2019
Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance
Schanz, J; (...); Haase, D
Article. 10.1002/gcc.22667. 2018
Clonal composition and its prognostic significance in patients with MDS
Schanz, J; (...); Int Working Grp Prognosis MDS
Meeting Abstract. 2018
Clonal Evolution Analysis Using Next Generation Sequencing (NGS) Panel in a Cohort of 3,025 Patients With Acute Myeloid Leukemia (AML)
Colmenares, Rafael; (...); Montesinos, Pau
Meeting Abstract. 2023
Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes
Martinez-Losada, C; (...); Sanchez-Garcia, J
Letter. 10.3324/haematol.2018.188433. 2018
Clonal Hematopoiesis Landscape in Patients with De Novo Acute Myeloid Leukemia By Deep Sequencing
Ibanez, Mariam; (...); Cervera, Jose
Meeting Abstract. 10.1182/blood.V128.22.598.598. 2016
CMV REACTIVATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FROM HLA-MATCHED AND HAPLOIDENTICAL DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE.
Article. 10.1016/j.jtct.2024.01.082. 2024
Co-culture of multiple myeloma cell lines and bone marrow mesenchymal stem cells in a 3D microgel environment.
Garcia-Briega, M Inmaculada; (...); Ribelles, Jose Luis Gomez
Article. 10.1016/j.bioadv.2025.214243. 2025
Comment on "Outcomes of autologous transplantation for multiple myeloma according to different induction regimens".
Article. 10.5581/1516-8484.20140020. 2014
Common seasonal respiratory virus infections in allogeneic stem cell transplant recipients during the SARS-COV-2 pandemic.
De La Puerta R; (...); Piñana JL
Article. 10.1038/s41409-021-01319-5. 2021
COMPARATIVE STUDY OF HEREDITARY SPHEROCYTOSIS USING FLOW CYTOMETRY AND OSMOTIC GLOBULAR FRAGILITY
Cordon Gallego, L.; (...); Sanz Alonso, M. A.
Meeting Abstract. 2015
COMPARATIVE STUDY OF THE CHARACTERISTICS OF THE DIAGNOSIS AND RESPONSE TO TREATMENT IN PATIENTS AGED=60 YEARS VS. <60 YEARS WITH ACQUIRED PURPLE THROMBOTIC THROMBOCYTOPENIC. RESULTS OF THE SPANISH REGISTRATION OF PTT (REPTT)
Aracil Eva, Frances; (...); Comos Javier, De la Rubia
Meeting Abstract. 2021
Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM)
Arana, Paula; (...); San Miguel, Jesus
Meeting Abstract. 2015
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Sargas, Claudia; (...); Montesinos, Pau
Article. 10.1038/s41408-023-00835-5. 2023
COMPARISON OF THREE PANELS OF NGS APPLICATION IN ONCOHEMATOLOGY TO DISCARD SOMATIC AND/OR GERMINAL VARIANTS
Guzman-Gimenez, C.; (...); Such, E.
Meeting Abstract. 2021
Complex Karyotype with >= 3 Cytogenetic Alterations is a New Marker of Worse Prognosis in Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)
Genesca, Eulalia; (...); Maria Ribera, Josep
Meeting Abstract. 2020
Comprehensive detection of CRLF2 alterations in acute lymphoblastic leukemia: a rapid and accurate novel approach.
Gil, Jose Vicente; (...); Barragan, Eva
Article. 10.3389/fmolb.2024.1362081. 2024
COMPREHENSIVE LONG-TERM FOLLOW-UP OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A REPORT FROM A SINGLE CENTRE
Sempere, A.; (...); Jarque, I.
Meeting Abstract. 2016
CONCORDANCE STUDY ON THE CATEGORIZATION OF NON-CANONICAL VARIANTS OF JAK2 GENE
Guzman-Gimenez, C.; (...); Such, E.
Meeting Abstract. 2021
CONCURRENT MUTATIONS IN ZRSR2 AND TET2 CAUSE SMD-COMPATIBLE ANOMALIES IN A MOUSE MODEL
Cristian, Garcia-Ruiz; (...); Alejandra, Sanjuan-Pla
Meeting Abstract. 2021
Concurrent Zrsr2 mutation and Tet2 loss promote myelodysplastic neoplasm in mice
Garcia-Ruiz C; (...); Sanjuan-Pla A
Article. 10.1038/s41375-022-01674-2. 2022
Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
Boluda, Blanca; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-160136. 2022
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Martínez-Cuadrón D; (...); CETLAM and PETHEMA groups
Article. 10.1007/s00277-018-3277-x. 2018
Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations
Adema V; (...); Solé F
Letter. 10.1111/bjh.13355. 2015
CRISPR to fix bad blood: a new tool in basic and clinical hematology
Gonzalez-Romero, E; (...); Sanjuan-Pla, A
Review. 10.3324/haematol.2018.211359. 2019
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality
Martínez-López J; (...); Lahuerta JJ
Article. 10.1182/blood-2015-04-638742. 2015
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
Puig N; (...); García-Sanz R
Article. 10.1038/leu.2013.217. 2014
Curative Strategy (GEM- CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd
Mateos, Maria-Victoria; (...); San-Miguel, Jesus F.
Meeting Abstract. 10.1182/blood-2021-148423. 2021
Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)
Mateos, Maria-Victoria; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2022-159606. 2022
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.
Mateos, Maria-Victoria; (...); San-Miguel, Jesus F
Article. 10.1200/JCO.23.02771. 2024
Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective
Hubel, K; (...); Corradini, P
Review. 10.1111/ejh.12362. 2015
CYTOGENETIC ANALYSIS IN REAL LIFE IN PATIENTS WITH MULTIPLE MYELOMA NEW DIAGNOSIS Results: FROM THE MULTIPLE MYELOMA STUDY GROUP OF THE VALENCIAN COMMUNITY (GREMI)
Gomez, Beltran Elena; (...); De la Rubia, Comos Javier
Meeting Abstract. 2020
Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping.
Diaz-Gonzalez, Alvaro; (...); Such, Esperanza
Article. 10.3390/cancers15113039. 2023
Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4
Kayser, Sabine; (...); Schlenk, Richard F.
Meeting Abstract. 10.1182/blood-2021-150281. 2021
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.
Kayser, Sabine; (...); Schlenk, Richard F.
Meeting Abstract. 10.3324/haematol.2022.281137. 2022
Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome.
Sánchez-Castro J; (...); Solé F
Article. 10.1016/j.leukres.2013.04.010. 2013
Characterization of a translocation that disrupts the COL4A5 gene in a girl with Alport syndrome by optical genome mapping
Orellana, Carmen; (...); Diaz, Alvaro
Meeting Abstract. 2024
CHARACTERIZATION OF CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA BY MEANS OF IMMUNOLOGICAL AND MOLECULAR TECHNIQUES: RESULTS OF THE GEPTT NATIONAL COLLECTION
Liquori, A.; (...); Gomez-Segui, I
Meeting Abstract. 2019
CHARACTERIZATION OF CHARACTERISTIC MORPHOLOGICAL ALTERATIONS IN PATIENTS WITH MDS/CMML AND GENE MUTATIONS OF SPLICING DIFFERENT TO SF3B1
Marco Ayala, J.; (...); Sanz, G.
Meeting Abstract. 2019
CHARACTERIZATION OF MUTATIONS ALTERING THE PROCESS OF SPLICING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
Boluda-Navarro, M.; (...); Cervera, J.
Meeting Abstract. 2018
CHARACTERIZATION OF RECURRENTLY MUTATED GENES IN ACUTE MYELOID LEUKEMIA DE NOVO WITH NORMAL KARPOTYPE BY TARGETED MASSIVE SEQUENCING
Ibanez, M.; (...); Cervera, J.
Article. 2015
CHARACTERIZATION OF THE GENOMIC AND TRANSCRIPTOMIC PROFILE OF THE ACUTE MYELOID LEUKEMIA (AML) SUBGROUP "CHROMATIN-SPLICEOSOME"
Alessandro, Liquori; (...); Zamora Jose, Cervera
Meeting Abstract. 2020
Chromosome 8 Abnormalities (8p Losses and 8q Gains) in Patients with Chronic Lymphocytic Leukemia (CLL) and Del(17p)
Blanco, Gonzalo; (...); Espinet, Blanca
Article. 2014
Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation.
Caballero JC; (...); Díez Campelo M
Article. 10.1007/s00277-019-03751-6. 2019
CHRONOLOGICAL AGE AS A PROGNOSTIC FACTOR IN PATIENTS WITH MULTIPLE MYELOMA NEW DIAGNOSIS NOT CANDIDATED FOR TRANSPLANTATION
Martinez Elena, Meseguer; (...); Comos Javier, De la Rubia
Meeting Abstract. 2021
Chronological age as a prognostic factor in transplant-ineligible patients with newly diagnosed Multiple Myeloma
Garcia Ruiz, Raquel; (...); de la Rubia, Javier
Meeting Abstract. 2021
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
Moreau, Philippe; (...); Goldschmidt, Hartmut
Letter. 10.1038/s41408-023-00805-x. 2023
Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML)
Gonzalez, Carmen; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2023-180646. 2023
DEEP INTRONIC MUTATIONS IN THE RUNX1 AND FLT3 GENES PRODUCE OPENING SPLICING IN PATIENTS WITH MYELODYSPLASIC SYNDROMES
Mireia, Boluda-Navarro; (...); Jose, Cervera
Meeting Abstract. 2021
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard and high risk myeloma.
Goicoechea I; (...); Paiva B
Article. 10.1182/blood.2020006731. 2020
DEEP SEQUENCING OF 23 GENES DESIGNATED BY TCGA STUDY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE
Ibanez, M.; (...); Cervera, J.
Meeting Abstract. 2016
Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies
Burgos, Leire; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2021-150092. 2021
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.
Burgos, Leire; (...); Paiva, Bruno
Article. 10.1200/JCO.22.01916. 2023
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
Lahuerta, JJ; (...); GEM (Grupo Español de Mieloma)
Article. 10.1200/JCO.2016.69.2517. 2017
Depth of Response of Isatuximab (Isa) plus Carfilzomib (K) and Dexamethasone (d) in Relapsed Multiple Myeloma: IKEMA Updated Analysis
Joseph, Mikhael; (...); Meletios, A. Dimopoulos
Article. 2022
Depth of response of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma: IKEMA updated analysis
Hajek, Roman; (...); Dimopoulos, Meletios A.
Meeting Abstract. 2022
DESCRIPTION OF THE CYTOOGENETIC ANOMALIES OF A SERIES OF PATIENTS OF THE SEHOP-PETHEMA 2013 PEDIATRIC PROTOCOL FOR THE TREATMENT OF B-LINE
Hidalgo Gomez, G.; (...); Ortega, M.
Meeting Abstract. 2018
Design and Validation of a Custom Next-Generation Sequencing Panel in Pediatric Acute Lymphoblastic Leukemia.
Gil, Jose Vicente; (...); Barragan, Eva
Article. 10.3390/ijms24054440. 2023
DESIGN AND VALIDATION OF AN ACUTE LYMPHOBLASTIC LEUKEMIA-TARGETED NEXT-GENERATION SEQUENCING PANEL
Gil, JV.; (...); Llop, M.
Meeting Abstract. 2023
Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale
Bonanad S; (...); GAH Group
Article. 10.1016/j.jgo.2015.03.003. 2015
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.
Article. 10.1182/blood-2012-08-452938. 2013
DEVELOPMENT OF A CELLULAR MODEL OF ACUTE MYELOID LEUKEMIA THROUGH CRISPR/CAS 9 TECHNOLOGY
Romero, EG; (...); Zamora, JVC
Meeting Abstract. 2017
DEVELOPMENT OF A MASSIVE SEQUENCING TEST FOR THE SIMULTANEOUS DETECTION OF POTENTIAL MUTATIONS AND CHROMOSOMAL ALTERATIONS IN PATIENTS WITH MYELODISPLASIC SYNDROMES
Liquori, A.; (...); Zamora, JVC
Meeting Abstract. 2017
Dexamethasone does not prevent malignant cell reintroduction in leukemia patients undergoing ovarian transplant: risk assessment of leukemic cell transmission by a xenograft model
Diaz-Garcia, C; (...); Pellicer, A
Article. 10.1093/humrep/dez115. 2019
DIAGNOSIS OF NOONAN SYNDROME AFTER STUDY OF NGS BY ESSENTIAL THROMBOCITEMIA
Marco Ayala, J.; (...); Sanz, M. A.
Meeting Abstract. 2018
Differentiation stage of myeloma plasma cells: biological and clinical significance
Paiva B; (...); San-Miguel JF
Article. 10.1038/leu.2016.211. 2017
Distinct mutational pattern of myelodysplastic syndromes with and without 5q-treated with lenalidomide
Adema, V; (...); Sole, F
Letter. 10.1111/bjh.16558. 2020
Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?
Article. 10.1182/bloodadvances.2019000680. 2019
Early-Onset Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) without SF3B1 Mutations in Adults: Enrichment with Germline Variants in Genes Responsible for Congenital Sideroblastic Anemias
Jauregui, Sandra Novoa; (...); Jerez, Andres
Meeting Abstract. 10.1182/blood-2023-185836. 2023
Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome
Cañigral C; (...); Sanz MA
Letter. 10.1007/s00277-013-1970-3. 2014
Effect of Caplacizumab in the Recovery of ADAMTS13 Level in Patients with Autoimmune Thrombotic Thrombocytopenic Purpura. Analysis from the Spanish Registry (REPTT)
Eva Mingot, Maria; (...); Del Rio Garma, Julio
Meeting Abstract. 10.1182/blood-2023-182876. 2023
Effect of CD8(+) Cell Content on Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies
Moscardó F; (...); Sanz GF
Article. 10.1016/j.bbmt.2014.06.038. 2014
EFFECT OF MISSENSE MUTATIONS IN THE SPLICING OF PATIENTS WITH ACUTE MYELOID LEUKAEMIA
Morote-Faubel, M.; (...); Cervera, J.
Meeting Abstract. 2019
EFFECTS OF B-MYB ABERRANT EXPRESSION ON HEMATOPOIETIC PROGENITOR CELL GROWTH AND DETECTION OF GENETIC VARIATIONS THAT MAY MODIFY ITS PROTEIN FUNCTION
Dolz, S.; (...); Sanz, M.
Article. 2013
Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: A randomised controlled trial
Meeting Abstract. 2018
El nuevo reto en oncologia: la secuenciacion NGS y su aplicacion a la medicina de precision.
Calabria I; (...); Castel V
Article. 10.1016/j.anpedi.2016.05.006. 2016
Elotuzumab plus bortezomib and dexamethasone (EBd) versus bortezomib and dexamethasone (Bd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM)-2-year follow-up
Palumbo, A; (...); Jakubowiak, A
Article. 2016
Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine
Diaz-Gonzalez, Alvaro; (...); Such, Esperanza
Meeting Abstract. 10.1182/blood-2023-180691. 2023
Epidemiology of Hereditary Thrombotic Thrombocytopenic Purpura (TTP) in Spain: Preliminary Results of a Study of the Spanish TTP Registry (REPTT)
Segui, Ines Gomez; (...); Garma, Julio Del Rio
Meeting Abstract. 2024
Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency.
Marin-Bejar, Oskar; (...); Giorgetti, Alessandra
Article. 10.3324/haematol.2022.282305. 2023
ERCC6L2 in Early-Onset Adult Myelodysplastic Syndrome without Pre-Existing Disorder
Carrillo-Tornel, Salvador; (...); Jerez, Andres
Meeting Abstract. 10.1182/blood-2022-168759. 2022
European Perspective on Multiple Myeloma Treatment Strategies in 2014
Ludwig H; (...); Palumbo A
Article. 10.1634/theoncologist.2014-0042. 2014
EVALUATION OF ANTI-LEUKEMIC IN VITRO TREATMENT WITH DEXAMETHASONE OF OVARIAN CORTEX PRIOR TO TRANSPLANTATION.
Diaz-Garcia, C.; (...); Pellicer, A.
Article. 10.1016/j.fertnstert.2015.07.815. 2015
Evaluation of minimal residual disease in relapsed/refractory multiple myeloma patients treated with venetoclax or placebo in combination with bortezomib and dexamethasone: BELLINI study analyses.
Moreau, P; (...); Kumar, S
Meeting Abstract. 2020
EVALUATION OF THE EFFECT OF DIFFERENT LIGANDS OF TLRS IN THE PROLIFERATION AND DIFFERENTIATION OF ACUTE MYELOID LEUKEMIA CELLS
Fernandez, JG; (...); Ribate, EV
Meeting Abstract. 2017
EVALUATION OF THE MUTATION OF FLT3 IN ACUTE MYELOID LEUKAEMIA: RESULTS OF THE DELPHI QUESTIONNAIRE OF THE SPANISH GROUP
Gomez-Casares, M. T.; (...); Sierra, J.
Meeting Abstract. 2019
Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm
Menezes J; (...); Cigudosa JC
Article. 10.1038/leu.2013.283. 2014
Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial
Mosquera Orgueira, Adrian; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2023-180710. 2023
Exploring the potential of optical genome mapping in soft-tissue and bone tumours
Mayordomo Aranda, E.; (...); Such Taboada, E.
Meeting Abstract. 2024
Factor XIII deficiency in two Spanish families with a novel variant in gene F13A1 detected by next-generation sequencing; symptoms and clinical management.
Moret A; (...); Bonanad S
Article. 10.1007/s11239-020-02065-z. 2020
FINAL ANALYSIS OF GLOBAL SURVIVAL OF THE FIRST TEST IN PATIENTS WITH MULTIPLE NEW DIAGNOSTIC MYELOMA
Oriol, A.; (...); Benboubker, L.
Meeting Abstract. 2017
FREQUENCY AND CLINICAL IMPACT OF CDKN2A/B GENE LOCUS IN AN ADULT T-ALL COHORT OF PATIENTS ENROLLED IN THE SPANISH PETHEMA GROUP PROTOCOLS
Genesca, E; (...); Ribera, JM
Meeting Abstract. 2017
Frequency of dicentrics and contamination levels in Ukrainian children and adolescents from areas near Chernobyl 20 years after the nuclear plant accident.
Montoro A; (...); Villaescusa JI
Article. 10.3109/09553002.2013.809172. 2013
Frequency of dicentrics and contamination levels in Ukrainian children and adolescents from areas near Chernobyl 20 years after the nuclear plant accident.
Montoro, A.; (...); Villaescusa, JI.
Article. 2013
FUNCTIONAL CLASSIFICATION OF DEEP INTRONIC VARIANTS IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA
Liquori, A.; (...); Cervera Zamora, J.
Meeting Abstract. 2019
FUNCTIONAL RECLASSIFICATION THROUGH MINIGENE TESTS OF MISSENSE VARIANTS WITH EFFECT ON SPLICING IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
Morote-Faubel, Mireya; (...); Cervera, Jose
Meeting Abstract. 2020
FUNCTIONAL STUDY OF SILENCED HMGCR GENE IN CELL LINES OF ACUTE MYELOID LEUKEMIA PATIENTS
De Matteo, B; (...); Zamora, JVC
Meeting Abstract. 2017
Further psychometric validation of the GAH scale: Responsiveness and effect size
Cruz-Jentoft, AJ; (...); GAH Group
Article. 10.1016/j.jgo.2016.12.008. 2017
Gastric Bleeding in Stem Cell Transplantation: A Focus on Gastric Vascular Ectasia Under Post-Transplant Cyclophosphamide, Sirolimus, and Mycophenolate Mofetil Prophylaxis.
Eirís J; (...); Sanz J
Article. 10.1016/j.jtct.2024.10.009. 2024
GENOME-WIDE ANALYSIS OF SINGLE NUCLEOTIDE POLYMORPHISM (SNPS) IN PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE
Ibanez, M.; (...); Cervera, J.
Meeting Abstract. 2016
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (vol 13, 2, 2022)
Lin, Wei-Yu; (...); Allan, James M.
Article. 10.1038/s41467-021-27679-6. 2022
GENOMIC ANALYSIS OF PML/RARA BREAKPOINTS IN PAIRED DIAGNOSIS/RELAPSE SAMPLES OF PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH ALL-TRANS RETINOIC ACID AND CHEMOTHERAPY
Iaccarino, L.; (...); Lo-Coco, F.
Meeting Abstract. 2017
GENOMIC AND TRANSCRIPTOMIC CHARACTERIZATION OF MYELODYSPLASTIC SYNDROMES/MYELOPROLIFERATIVE NEOPLASMS
Acha, P.; (...); Sole, F.
Meeting Abstract. 10.1016/j.leukres.2023.107253. 2023
GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
Bernard, E.; (...); Papaemmanuil, E.
Meeting Abstract. 10.1016/j.leukres.2023.107146. 2023
Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea.
Alvarez-Larrán A; (...); Hernández-Boluda JC
Letter. 10.1038/s41375-020-0849-2. 2020
Genomic profiling of high-risk smoldering myeloma patients treated with a curative strategy: a biological study of the phase II GEM CESAR clinical trial
Medina, Alejandro; (...); Garcia-Sanz, Ramon
Meeting Abstract. 2023
Genotype FBN1/Phenotype relationship in a cohort of patients with Marfan syndrome.
Hernándiz A; (...); Sepúlveda P
Article. 10.1111/cge.13879. 2020
Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.
de la Rubia J; (...); Bonanad, Santiago
Article. 10.1016/j.jgo.2022.10.016. 2022
GERMINAL PREDISPOSITION IN PATIENTS WITH MYELOID NEOPLASMS: ASSOCIATION BETWEEN MOLECULAR DISORDERS AND CLINICAL HISTORY
Marta, Santiago; (...); Jose, Cervera
Meeting Abstract. 2021
Germline and Acquired Genetic Variants in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction
Chen-Liang, TH; (...); Jerez, A
Meeting Abstract. 10.1182/blood-2018-99-116045. 2018
Germline assessment for alloHSCT candidates over 50 years: A 'Fast-Track' screening in myeloid neoplasms.
Torres-Esquius S; (...); Jerez A
Article. 10.1111/bjh.19460. 2024
Germline Predisposition in Myeloid Neoplasms Aged =50: A Novel Approach for Allogeneic Stem Cell -Transplantation Decision-Making
Torres-Esquius, Sara; (...); Jerez, Andres
Meeting Abstract. 10.1182/blood-2023-179234. 2023
GERMLINE PREDISPOSITION TO MYELOID MALIGNANCIES IN A CONSECUTIVE COHORT OF 183 PATIENTS
Santiago, M.; (...); Cervera-Zamora, J.
Meeting Abstract. 10.1016/j.leukres.2023.107247. 2023
GUIDELINES OF PRESCRIPTION IN FIRST LINE OF PATIENTS WITH MULTIPLE MYELOMA NOT CANDIDATES TO TRANSPLANTATION STRATIFIED BY AGE IN REAL LIFE IN SPAIN BETWEEN 2012 AND 2016
Cejalvo, M. J.; (...); Sarra, J.
Meeting Abstract. 2019
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.
Solana-Altabella A; (...); Montesinos P
Article. 10.1111/ejh.13604. 2021
Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia.
Vega-Garcia N; (...); Camós M
Article. 10.3390/jpm10040244. 2020
HIDDEN MDS: A PROSPECTIVE STUDY TO CONFIRM OR EXCLUDE MDS IN PATIENTS WITH ANEMIA OF UNCERTAIN ETIOLOGY
Bastida Bermejo, J. M.; (...); Diez-Campelo, M.
Meeting Abstract. 2016
Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiology
Bastida, JM; (...); Diez-Campelo, M
Article. 10.1111/ijlh.12933. 2019
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience
Rodriguez-Otero, Paula; (...); Gutierrez, Norma
Meeting Abstract. 2023
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience
Gonzalez-Calle, Veronica; (...); Gutierrez, Norma C.
Article. 10.1002/hem3.70031. 2024
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
de Arriba de la Fuente, Felipe, Montes Gaisan, Carmen, de la Rubia Comos, Javier
Review. 10.3390/cancers15010155. 2023
Human Mesenchymal Stem Cells Growth and Osteogenic Differentiation on Piezoelectric Poly(vinylidene fluoride) Microsphere Substrates
Sobreiro-Almeida, R.; (...); Sempere, A.
Article. 10.3390/ijms18112391. 2017
Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels
Guillaumet-Adkins A; (...); Monk D
Article. 10.1186/1756-8722-7-4. 2014
Identification of Leukemia-Associated Immunophenotypes by Databaseguided Flow Cytometry Provides a Highly Sensitive and Reproducible Strategy for the Study of Measurable Residual Disease in Acute Myeloblastic Leukemia
Pinero, Paula; (...); Tarin, Fabian
Article. 10.3390/cancers14164010. 2022
IDIOPATHIC UPPER GASTROINTESTINAL BLEEDING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: AN UNPRECEDENTED COMPLICATION
Eiris, Juan; (...); Balaguer-Rosello, Aitana
Meeting Abstract. 2024
IgG antibody response to pneumococcal-conjugated vaccine (Prevenar®13) in children with immunodeficiency disorders.
Garrido-Jareño M; (...); Pemán-García J
Article. 10.1007/s00430-022-00759-0. 2023
IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial
Ribera, Jordi; (...); Ribera, Josep-Maria
Meeting Abstract. 10.1182/blood-2022-162159. 2022
Imiquimod inhibits growth and induces differentiation of myeloid leukemia cell lines
Villamon, E; (...); Gil, ML
Article. 10.1186/s12935-018-0515-1. 2018
Immune biomarkers of survival and infection-related mortality in multiple myeloma (MM) patients treated with lenalidomide and dexamethasone (Rd)
Maia, Catarina; (...); Paiva, Bruno
Meeting Abstract. 2022
Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)
Maia, Catarina; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2022-163058. 2022
Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies.
Article. 10.1007/s00277-024-05758-0. 2024
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis
Paiva B; (...); Spanish Myeloma Group
Article. 10.1182/blood-2015-10-662320. 2016
Immune thrombotic thrombocytopenic purpura in older patients: Results from the Spanish TTP Registry (REPTT).
Gomez-Segui, I; (...); de la Rubia Comos, J
Article. 10.1111/bjh.19109. 2023
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Perez, C; (...); Programa Estudio Terapeutica Hemop
Article. 10.1182/blood.2019004537. 2020
Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer
Salvador-Coloma, C; (...); de Mora, JF
Article. 10.1016/j.ejca.2020.08.020. 2020
Immunosuppressive profiles in liquid biopsy predict response to neoadjuvant chemotherapy in triple negative breast cancer
Salvador-Coloma, C; (...); Santaballa, A
Meeting Abstract. 10.1158/1538-7445.SABCS18-P3-11-16. 2019
Immunotherapy in multiple myeloma.
Asensi Cantó P, Arnao Herraiz M, de la Rubia Comos J
Article. 10.1016/j.medcli.2023.11.019. 2024
Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1080/10428194.2016.1231405. 2017
IMPACT OF ALLELIC STATUS OF TP53 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML)
Ibanez, Mariam; (...); Sanz, Guillermo
Meeting Abstract. 2020
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1080/10428194.2020.1839650. 2020
Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study.
Ayala, Rosa; (...); Montesinos, Pau
Article. 10.3390/cancers14235799. 2022
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.
Paiva B; (...); PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) coop
Article. 10.1038/s41375-021-01126-3. 2021
Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1038/tpj.2017.19. 2018
Impact of natural-killer immune reconstitution on the development of cytomegalovirus infection, non-relapse mortality, and graft versus host disease after allogeneic stem cell transplantation
Rodriguez-Veiga, R.; (...); Sanz, M. A.
Meeting Abstract. 2015
IMPACT OF POSTTRANSPLANT CYCLOPHOSPHAMIDE ON TRANSFUSION REQUIREMENTS IN HLA MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.
Marco-Ayala, Javier; (...); Solves, Pilar
Article. 10.1016/j.jtct.2023.01.009. 2023
Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases
Palomo L; (...); Zamora L
Article. 10.1002/ajh.24227. 2016
Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7.
Crisà E; (...); Mufti GJ
Article. 10.1038/s41375-020-0728-x. 2020
Impact of t(11;14) according to induction regimen in newly diagnosed transplant-eligible multiple myeloma patients: long term follow-up of GEM05MENOS65 and GEM2012 PETHEMA/GEM studies
Moreno, David; (...); Rosinol, Laura
Meeting Abstract. 2021
Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Meeting Abstract. 2015
Impact on Outcomes of Human Leukocyte Antigen Matching by Allele-Level Typing in Adults with Acute Myeloid Leukemia Undergoing Umbilical Cord Blood Transplantation
Article. 10.1016/j.bbmt.2013.10.016. 2014
IMPLEMENTATION OF MASSIVE SEQUENCING TECHNOLOGIES TO THE DETECTION OF MUTATIONS IN THE ABL KINASE DOMAIN OF BCR-ABL REORDERING
Simarro, CS; (...); Gonzalez, EB
Meeting Abstract. 2017
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)
Bernard, Elsa; (...); Elias, Harold K
Article. 10.1038/s41591-021-01367-w. 2021
Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Bernard, E; (...); Papaemmanuil, E
Article. 10.1038/s41591-020-1008-z. 2020
Improved outcomes in allo-HCT for multiple myeloma patients with thiotepa-busulfan-fludarabine conditioning regimen and post-transplant cyclophosphamide, sirolimus and mycophenolate mofetil
de la Rubia, Javier; (...); Sanz, Miguel
Meeting Abstract. 2023
In vitro all-trans retinoic acid sensitivity of acute myeloid leukemia blasts with NUP98/RARG fusion gene
Letter. 10.1007/s00277-014-2073-5. 2014
IN VIVO MODELS FOR THE FUNCTIONAL STUDY OF CO-OCCURRING GENETIC AND EPIGENETIC MUTATIONS IN MYELODYSPLASTIC SYNDROMES
Martinez-Valiente, C.; (...); Sanjuan-Pla, A.
Meeting Abstract. 2018
IN VIVO MODELS TO STUDY THE COOPERATION BETWEEN SPLICING AND DNA METHYLATION IN MYELODYSPLASTIC SYNDROMES
Martinez-Valiente, Cristina; (...); Sanjuan-Pla, Alejandra
Meeting Abstract. 2020
INCIDENCE AND CHARACTERISTICS OF BACTERIAL INFECTIONS DURING THE THERAPY OF INDUCTION IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH NEW DRUGS. STUDY OF 67 PATIENTS FROM A SINGLE CENTRE
Martinez Garcia, M. F.; (...); Sanz Alonso, M. A.
Meeting Abstract. 2015
Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.
Rodríguez-Veiga R; (...); Sanz GF
Article. 10.1007/s00277-019-03744-5. 2019
Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion.
Castillo MI; (...); Díaz TM
Article. 10.1002/cam4.6300. 2023
Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia
Boluda, Blanca; (...); Montesinos, Pau
Article. 10.3390/cancers15082267. 2023
Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
Sirenko, Maria; (...); Papaemmanuil, Elli
Meeting Abstract. 10.1182/blood-2022-162397. 2022
Incidence, Diagnosis, and Outcome of Acquired Thrombotic Thrombocytopenic Purpura (aTTP): A Nationwide Survey By the Spanish Apheresis Group
Izquierdo, Maria Cristina Pascual; (...); Salinas, Ramon
Meeting Abstract. 10.1182/blood-2019-123258. 2019
Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura
Pascual-Izquierdo, C; (...); Salinas, R
Article. 10.1002/jca.21894. 2021
Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide.
Asensi Cantó P; (...); Sanz J
Article. 10.1038/s41409-024-02391-3. 2024
Incidence, risk factors, and outcomes of BK hemorrhagic cystitis in hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplant cyclophosphamide.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2024.12.006. 2024
INCORPORATION OF DARATUMUMAB IN COMBINATION TO THE THERAPEUTIC PANORAMA OF PATIENTS WITH MULTIPLE MYELOMA IN RECAIDA: RESULTS OF HABITUAL CLINICAL PRACTICE IN SPAIN. GEMINI STUDY
Rios-Tamayo, R.; (...); Mateos Manteca, M., V
Meeting Abstract. 2019
Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1080/10428194.2017.1323267. 2017
Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1097/FPC.0000000000000431. 2021
Influence of Single Nucleotide Polymorphisms in Anthracycline Metabolism Pathway in Standard Induction of Acute Myeloid Leukemia
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Meeting Abstract. 2015
Influence of TP53 Gene Mutations and its Allelic Status in Myelodysplastic Syndromes with Isolated 5q Deletion.
Montoro, Maria Julia; (...); Valcarcel, David
Article. 10.1182/blood.2024023840. 2024
Infusion of Haploidentical Stem Cell after Consolidation in Younger Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase I-II Study
Boluda, Blanca; (...); Sanz, Miguel A.
Meeting Abstract. 10.1182/blood.V128.22.1614.1614. 2016
IN-SILICO AND IN VITRO STUDY OF MUTATIONS THAT ALTER THE SPLICING PROCESS IN PATIENTS WITH MYELODISPLASIC SYNDROMES
Boluda-Navarro, M.; (...); Cervera, J.
Meeting Abstract. 2019
INTERLABORATORY STUDY OF MUTATIONS DETECTION IN MYELOID NEOPLASMS THROUGH NEW GENERATION SEQUENCING
Rodriguez, CF; (...); Bellosillo, B
Meeting Abstract. 2017
INTRACHROMOSOMAL AMPLIFICATION OF CHROMOSOME 21 (IAMP21): STUDY IN A SERIES OF 894 LLA-B OF PEDIATRIC AND 74 LLA-B OF ADULT
Hidalgo Gomez, G.; (...); Ortega, M.
Meeting Abstract. 2018
Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
Blanes M; (...); de la Rubia J
Article. 10.1016/j.bbmt.2012.08.009. 2013
Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma
Blanes, M; (...); de la Rubia, J
Letter. 10.1007/s00277-019-03663-5. 2019
Intravenous Busulfan-Melphalan vs Melphalan as Preparative Regimen for Newly Diagnosed Multiple Myeloma: Long-Term Follow-Up of a Case-Control Study
Blanes, M; (...); de la Rubia, J
Meeting Abstract. 10.1016/j.clml.2019.09.473. 2019
Intravenous busulphan plus melphalan versus melphalan alone as conditioning regimen for newly diagnosed patients with multiple myeloma: Long-term follow-up of a matched case-controlled study
Blanes, M; (...); de la Rubia, J
Meeting Abstract. 2019
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis.
Hajek, Roman; (...); Dimopoulos, Meletios A.
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.8034. 2021
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
Dimopoulos, Meletios A.; (...); Hajek, Roman
Article. 10.1002/ajh.26602. 2022
Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial
Puig, Noemi; (...); Victoria Mateos, Maria
Meeting Abstract. 10.1182/blood-2023-182964. 2023
ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results
Ghobrial, Irene; (...); Mateos, Maria-Victoria
Meeting Abstract. 2021
JUVENILE MYELOMONOCITIC LEUKEMIA IN PATIENTS WITH NOONAN SYNDROME AND NOONAN-LIKE SYNDROMES: EXPERIENCE OF THE SPANISH YOUTH MYELOMONOCITIC LEUKEMIA REGISTRATION
Arques Martinez, L.; (...); Catala Temprano, A.
Meeting Abstract. 2019
Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations
Blanco, G; (...); Espinet, B
Article. 10.18632/oncotarget.13106. 2016
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker L; (...); FIRST Trial Team
Article. 10.1056/NEJMoa1402551. 2014
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.
Mateos MV; (...); San Miguel JF
Article. 10.1056/NEJMoa1300439. 2013
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial
Mateos, MV; (...); Miguel, JFS
Article. 10.1016/S1470-2045(16)30124-3. 2016
Lineage switch from B lymphoblastic leukemia with KMT2A-rearranged to mixed-phenotype acute leukemia under daratumumab
Marco-Ayala, J; (...); Peris, MLS
Editorial Material. 10.5045/br.2020.2020059. 2020
Longitudinal outcome over four decades of allogeneic stem cell transplantation: a single center experience.
Sanz, Miguel Angel; (...); Sanz, Jaime
Article. 10.1038/s41409-024-02319-x. 2024
MASS SEQUENCING DIRECTED TO THE STUDY OF REARRANGEMENTS AND CHANGES IN GENIC EXPRESSION IN ACUTE MYELOID LEUKEMIA
Sargas Simarro, C.; (...); Barragan Gonzalez, E.
Meeting Abstract. 2019
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.
Puig, Noemi; (...); Mateos, Maria-Victoria
Article. 10.1182/bloodadvances.2021006762. 2022
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
Paiva B; (...); GEM (Grupo Español de Mieloma)
Article. 10.1200/JCO.19.01231. 2020
Minimal Residual Disease Detection By Single Cell DNA Sequencing Technology: A Feasible Approach for Clinical Application and Identification of the Landscape of MRD Clones
Alfonso Pierola, Ana; (...); Prosper, Felipe
Meeting Abstract. 10.1182/blood-2023-188865. 2023
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
Paiva B; (...); Grupo Español de Mieloma
Article. 10.1182/blood-2016-03-705319. 2016
MODELING OF IDH2 GENE MUTATIONS IN THE CAENORHABDITIS ELEGANS ORGANISM. DEVELOPMENT OF A NEW STUDY MODEL
Gonzalez-Romero, E.; (...); Cervera-Zamora, J.
Meeting Abstract. 2021
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
Sirenko, Maria; (...); Papaemmanuil, Elli
Article. 10.1182/blood.2023023723. 2024
MOLECULAR APPROACH TO CHRONIC LYMPHOPROLIFERATIVE SYNDROMES IN THE DAILY CLINICAL PRACTICE OF A SINGLE CENTER
Mariam, Ibanez; (...); Irene, Luna
Meeting Abstract. 2021
MOLECULAR CHARACTERIZATION OF ACUTE LEUKAEMIA OF CHILD, ADOLESCENT AND YOUNG ADULT THROUGH MASSIVE GUIDED SEQUENCING
Llop Garcia, M.; (...); Barragan Gonzalez, E.
Meeting Abstract. 2019
MOLECULAR CHARACTERIZATION OF CELLULAR MODELS OF ACUTE MYELOBLASTIC LEUKEMIA (AML) BY MASS SEQUENCING
Navarro, MB; (...); Cervera, J
Meeting Abstract. 2017
MOLECULAR CHARACTERIZATION OF MULTIPLE MYELOMA PATIENTS BY USING A SINGLE ENRICHMENT PANEL IDENTIFYING SNVS, INDELS, CNVS AND TRANSLOCATIONS
Juan Manuel, Rosa-Rosa; (...); Joaquin, Martinez-Lopez
Meeting Abstract. 2021
MOLECULAR CHARACTERIZATION OF PATIENTS WITH HEREDITARY MYELOID NEOPLASIAS THROUGH MASS SEQUENCING
Pardo-Lorente, N.; (...); Cervera, J.
Meeting Abstract. 2018
MOLECULAR CHARACTERIZATION OF VARIANTS THAT ALTER SPLICING (VAS) IN PATIENTS WITH MYELODYSPLASIC SYNDROMES
Boluda-Navarro, M.; (...); Cervera, J.
Meeting Abstract. 2020
Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications
Bernard, Elsa; (...); Papaemmanuil, Elli
Meeting Abstract. 10.1182/blood-2023-186863. 2023
Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications.
Bernard, Elsa; (...); Papaemmanuil, Elli
Article. 10.1182/blood.2023023727. 2024
Monosomal karyotype in MDS: explaining the poor prognosis?
Schanz J; (...); Haase D
Article. 10.1038/leu.2013.187. 2013
Multiple Congenital Anomalies-Hypotonia-Seizures Syndrome 2 Caused by a Novel PIGA Variant Not Associated with a Skewed X-Inactivation Pattern
Gabaldon-Albero, Alba; (...); Martinez, Francisco
Article. 10.3390/genes15060802. 2024
Multiple phenotypes and epigenetic profiles in a three-generation family history with GATA2 deficiency.
Romero-Moya, Damia; (...); Giorgetti, Alessandra
Article. 10.1038/s41375-025-02519-4. 2025
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion
Sánchez-García J; (...); Sanz GF
Article. 10.1111/bjh.12876. 2014
MUTATIONAL PROFILE ENABLES THE IDENTIFICATION OF A HIGH RISK SUBGROUP IN MYELODYSPLASTIC SYNDROMES WITH ISOLATED TRISOMY 8
Toribio Castello, S. M.; (...); Del Rey, M.
Meeting Abstract. 10.1016/j.leukres.2023.107189. 2023
Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8.
Toribio-Castelló S; (...); Hernández-Rivas JM
Article. 10.3390/cancers15153822. 2023
Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
Cedena, MT; (...); Martinez-Lopez, J
Article. 10.18632/oncotarget.22157. 2017
Mutually-Exclusive Pathways between IKZF1 plus and RAS Mutations and TP53 double-Hit Alterations Lead Relapse in B-Other, Ph-like and Hyperdiploidy Genetic Groups in Adult B- Cell Acute Lymphoblastic Leukemia
Navas Acosta, Josgrey Del Valle Del Valle; (...); Hernandez-Rivas, Jesus Maria
Meeting Abstract. 10.1182/blood-2023-182163. 2023
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations
Martin, I; (...); Tormo, M
Article. 10.1111/bjh.17675. 2021
MYELODYSPLASTIC SYNDROMES WITH 20Q DELETION: INCIDENCE, PROGNOSTIC VALUE AND THERAPEUTIC IMPACT OF CHROMOSOMAL ALTERATIONS OF THE ASXL1 GENE AND GENETIC MUTATIONS
Martin, Castillo, I; (...); Tormo, Diaz M.
Meeting Abstract. 2020
Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS)
Martin, I; (...); Sanz, G
Article. 10.1080/10428194.2016.1246725. 2017
NEUROLOGIC COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CALCINEURIN-FREE GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS
Balaguer Rosello, Aitana; (...); Sanz, Jaime
Meeting Abstract. 2023
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
New mutations found by Next-Generation Sequencing screening of Spanish patients with Nemaline Myopathy
Moreau-Le Lan, S; (...); Pedrola, L
Article. 10.1371/journal.pone.0207296. 2018
Next generation sequencing in bleeding disorders: two novel variants in the F5 gene (Valencia-1 and Valencia-2) associated with mild factor V deficiency.
Moret, A; (...); Bonanad, S
Article. 10.1007/s11239-019-01911-z. 2019
Next-Generation DNA Sequencing-Based Gene Panel for Diagnosis and Genetic Risk Stratification in Onco-Hematology
Gargallo P; (...); Calabria I
Article. 10.3390/cancers14081986. 2022
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial.
Rosa-Rosa, Juan Manuel; (...); Martinez-Lopez, Joaquin
Article. 10.3390/cancers14205169. 2022
NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy.
Hurtado-Navarro L; (...); Ferrer-Marín F
Article. 10.1016/j.xcrm.2023.101329. 2023
Novel microgel culture system as semi-solid three-dimensional in vitro model for the study of multiple myeloma proliferation and drug resistance
Clara-Trujillo S; (...); Gómez Ribelles JL
Article. 10.1016/j.bioadv.2022.212749. 2022
Novel real-time polymerase chain reaction assay for simultaneous detection of recurrent fusion genes in acute myeloid leukemia.
Dolz S; (...); Sanz MA
Article. 10.1016/j.jmoldx.2013.04.003. 2013
Observational study to describe the impact of treatment combinations with Daratumumab versus other alternative regimens in patients with relapsed / refractory multiple myeloma. Spain real world evidence (RWE) data. GeminiS study
Tamayo, RR; (...); Mateos, MV
Meeting Abstract. 10.1016/j.clml.2019.09.245. 2019
OPTIMIZATION OF THE EFFICIENCY OF GENETIC EDITING OF HEMAPOYETIC PROGENITOR CELLS USING CRISPR/CAS9 RIBONUCLEOPROTEINS
Martinez-Valiente, C.; (...); Sanjuan-Pla, A.
Meeting Abstract. 2019
Osteogenic differentiation of human mesenchymal stem cells on electroactive substrates.
Tamaño-Machiavello MN; (...); Ribelles JLG
Article. 10.1016/j.heliyon.2024.e28880. 2024
Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes.
Caballero, Juan Carlos; (...); Diez Campelo, Maria
Article. 10.1177/20406207231218157. 2024
Overactivation of the NLRP3 Inflammasome in Chronic Myelomonocytic Leukemia KRAS Mutated Patients Can be Detected By the Apoptosis- Associated Speck-like Protein (ASC) and Reverted By IL1 beta Inhibitors
Hurtado-Navarro, Laura; (...); Marin, Francisca Ferrer
Meeting Abstract. 10.1182/blood-2021-153686. 2021
P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results (vol 21, pg S109, 2021)
Ghobrial, Irene M.; (...); Mateos, Maria-Victoria
Correction. 10.1016/j.clml.2022.03.011. 2022
Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients
Ibanez, Mariam; (...); Luna I
Article. 10.3390/diagnostics12040953. 2022
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
San-Miguel, JF; (...); Richardson, PG
Article. 10.1016/S1470-2045(14)70440-1. 2014
PCR-Based Strategy for Introducing CRISPR/Cas9 Machinery into Hematopoietic Cell Lines.
González-Romero E; (...); Vázquez-Manrique RP
Article. 10.3390/cancers15174263. 2023
Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
Sargas, Claudia; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-166639. 2022
Pilot Inter-Laboratory Comparison Study of Optical Genome Mapping Analysis for Cytogenomic Characterization of Hematological Malignancies: A Spanish Multicentric Study
Puiggros, Anna; (...); Espinet, Blanca
Meeting Abstract. 10.1182/blood-2022-166293. 2022
Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.
Lazzari, Lorenzo; (...); Sanz, Jaime
Article. 10.1038/s41409-022-01725-3. 2022
Practical guide to emergency treatment of thrombotic microangiopathy
Romero S; (...); Grupo de Microangiopatía Trombótica del Hospital Universitario y Politécnico La
Editorial Material. 10.1016/j.medcli.2018.01.013. 2018
Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment
Minguela, Alfredo; (...); Periago, Adela
Article. 2021
Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment.
Minguela, Alfredo; (...); Periago, Adela
Article. 2021
Preferential Genetic Pathways Lead to Relapses in Adult B-Cell Acute Lymphoblastic Leukemia
Navas-Acosta, Josgrey; (...); Hernandez-Rivas, Jesus Maria
Article. 10.3390/cancers16244200. 2024
Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3-PBX1 treated with measurable residual disease-oriented protocols
Ribera, Jordi; (...); Ribera, Josep-Maria
Article. 10.1111/bjh.17844. 2021
Prognostic Impact of Anthracycline Metabolism Gene Polymorphisms in Newly Diagnosed Acute Myeloid Leukemia Adults
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Article. 2014
Prognostic Impact of Cytarabine Pathway Gene Polymorphisms in Acute Myeloid Leukemia Adults Undergoing Induction Chemotherapy
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Article. 2014
Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes
Nomdedeu, M; (...); Costa, D
Article. 10.1002/gcc.22333. 2016
Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts
Martin, I; (...); Sanz, G
Article. 10.1038/s41408-017-0016-9. 2017
PROGNOSTIC IMPACT OF TRANSPORTER GENE POLYMORPHISMS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA ADULTS
Megias Vericat, J. E.; (...); Sanz, M. A.
Article. 2015
Prognostic Significance of Complex Karyotype and Monosomal Karyotype in Adult Patients With Acute Lymphoblastic Leukemia Treated With Risk-Adapted Protocols
Motlló C; (...); Feliu E
Article. 10.1002/cncr.28950. 2014
Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials
Paiva, Bruno; (...); San Miguel, Jesus
Meeting Abstract. 2015
Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials
Arana P; (...); San Miguel JF
Article. 10.1038/leu.2017.320. 2018
PROGNOSTIC VALUE OF B-MYB AND ITS REGULATION BY MIRNAS IN ACUTE MYELOID LEUKEMIA
LLop, M.; (...); Angel Sanz, M.
Article. 2013
Prognostic Value of Chromosome 1 Abnormalities in Myelodysplastic Syndrome
Ibarrondo, Paloma; (...); Batlle-Lopez, Ana
Article. 2014
Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study
Arana, Paula; (...); San Miguel, Jesus
Meeting Abstract. 2015
PROPOSED MOLECULAR CLASSIFICATION OF ACUTE MYELOBLASTIC LEUKEMIA (AML) BASED ON SPLICING EVENTS
Liquori, A.; (...); Cervera Zamora, J.
Meeting Abstract. 2021
Protein-Functionalized Microgel for Multiple Myeloma Cells' 3D Culture.
Marín-Payá JC; (...); Gomez Ribelles, Jose Luis
Article. 10.3390/biomedicines10112797. 2022
PURE ERYTHROID SARCOMA IN A PEDIATRIC PATIENT. A CASE REPORT AND REVIEW OF THE LITERATURE
Manresa Manresa, P.; (...); Rodrigo, FT
Meeting Abstract. 2017
Púrpura trombocitopénica trombótica inmune: sospecha y manejo básico en los servicios de urgencias. Revisión y consenso de un grupo de expertos de las sociedades científicas SEHH y SEMES.
Pascual-Izquierdo, Cristina; (...); de la Rubia Comos, Javier
Article. 10.55633/s3me/E099.2023. 2023
QUANTIFICATION OF CIRCULATING TUMOR CELLS IS THE MOST RELEVANT PROGNOSTIC FACTOR AT DIAGNOSIS IN PATIENTS WITH MULTIPLE MYELOMA, WHO ARE TRANSPLANT CANDIDATES, Abstracts
Juan-Jose, Garces; (...); Bruno, Paiva
Meeting Abstract. 2021
Radioprotective activity and cytogenetic effect of resveratrol in human lymphocytes: an in vitro evaluation.
Sebastià N; (...); Montoro A
Article. 10.1016/j.fct.2012.10.013. 2013
Radioprotective activity and cytogenetic effect of resveratrol in human lymphocytes: an in vitro evaluation.
Sebastià, N; (...); Montoro, A.
Article. 2013
Real world evaluation of teclistamab in patients with RRMM: results from the IMF immunotherapy database project
Costa, Luciano; (...); Wong, Sandy
Meeting Abstract. 2023
Real-world effectiveness of caplacizumab vs standard of care in immune thrombotic thrombocytopenic purpura.
Pascual Izquierdo, Maria Cristina; (...); Del Rio-Garma, Julio
Article. 10.1182/bloodadvances.2022008028. 2022
Real-World Experience in Extracorporeal photopheresisfor adults with graft-versus-host disease.
Asensi Cantó P; (...); Gómez-Seguí I
Article. 10.1016/j.jtct.2023.09.001. 2023
Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: review of 5,654 patients with an evaluable karyotype.
Costa D; (...); Nomdedeu B
Article. 10.1002/gcc.22071. 2013
Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura.
Mingot Castellano, Maria Eva; (...); Grp Espanol Aferesis GEA
Practice Guideline. 10.1016/j.medcli.2021.03.040. 2022
Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part I: update on laboratory tests for the study of monoclonal gammopathies.
Cardenas, Maria C.; (...); Cruz-Iglesias, Elena
Article. 10.1515/cclm-2023-0326. 2023
Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part II: methodological and clinical recommendations for the diagnosis and follow-up of monoclonal gammopathies
Cardenas, Maria C.; (...); Cruz-Iglesias, Elena
Article. 10.1515/cclm-2023-0325. 2023
REDEFINING OUTCOMES IN IMMUNE TTP: AN INTERNATIONAL WORKING GROUP CONSENSUS REPORT.
Cuker A; (...); Scully M
Article. 10.1182/blood.2020009150. 2021
Reduced incidence of neurologic complications after allogeneic hematopoietic stem cell transplantation with calcineurin-free graft-versus-host disease prophylaxis.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.07.008. 2023
Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma.
Puig, Noemi; (...); Paiva, Bruno
Article. 10.3390/cancers13194924. 2021
Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype.
Mallo, Mar; (...); Sole, Francesc
Article. 10.1002/jha2.651. 2023
REMOVAL OF GERMINAL LINE MUTATIONS IN PATIENTS WITH MDS AND AML: WHO SHOULD BE PERFORMED?
Santiago, Marta; (...); Cervera, Jose
Meeting Abstract. 2020
Renal response to rescue treatments in Relapsed Refractory Multiple Myeloma (RRMM) patients with renal impairment: final data of a large, observational, prospective study (MIR50)
Garcia-Guinon, Antonio; (...); de la Rubia, Javier
Meeting Abstract. 2021
Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.
Mallo M; (...); Solé F
Article. 10.1111/bjh.12354. 2013
Revealing the mutational landscape of acute promyelocytic leukemia
Editorial Material. 10.21037/tcr.2017.02.47. 2017
RNA Sequencing Analysis for the Identification of a PCM1/PDGFRB Fusion Gene Responsive to Imatinib
Such, E; (...); Cervera, J
Article. 10.1159/000497348. 2019
Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia
Ribera, Jordi; (...); Ribera, Josep-Maria
Meeting Abstract. 10.1182/blood-2023-186265. 2023
Screening for IDH mutations in chronic myelomonocytic leukemia.
Ibañez M; (...); Sanz MA
Letter. 10.3109/10428194.2012.701295. 2013
Selective IgA Deficiency and Blood Component Transfusion: In Search of the Lost Evidence
Solves, Pilar; (...); de la Rubia, Javier
Article. 10.3390/hemato5020009. 2024
SEQUENCING OF THE EXOME IN THE RECALLING OR REFRACTORY AML
Simarro Claudia, Sargas; (...); Eva, Barragan
Meeting Abstract. 2021
Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic
Martinez-Lopez, Joaquin; (...); San-Miguel, Jesus F.
Meeting Abstract. 10.1182/blood-2021-149192. 2021
Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons.
Seguí IG; (...); de la Rubia J
Article. 10.1080/17474086.2024.2318347. 2024
Simplified in-House Deep Sequencing Method of Inmunoglobulin Genes for Minimal Residual Dissease Quantification and Risk Stratification in Multiple Myeloma
Sanchez-Vega, Beatriz; (...); Martinez Lopez, Joaquin
Article. 2015
SINGLE CELL-LEVEL CHARACTERIZATION OF THE IMMUNE MICROENVIRONMENT OF MULTIPLE MYELOMA IDENTIFIES CD27 NEGATIVE T LYMPHOCYTES AS TUMOR SPECIFIC
Perez, Cristina; (...); Paiva, Bruno
Meeting Abstract. 2020
Single nucleotide polymorphism array karyotyping: a diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing.
Arenillas L; (...); Solé F
Article. 10.1002/gcc.22112. 2013
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics: a retrospective study of the PETHEMA/Spanish Myeloma Group (GEM)
Villalba, Ana; (...); De la Rubia, Javier
Meeting Abstract. 2022
Single-Cell Characterization of Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-negative T cells as Potential Tumor-Reactive Lymphocytes
Botta, C; (...); Paiva, B
Meeting Abstract. 10.1016/j.clml.2019.09.581. 2019
Single-Nucleotide Polymorphism Array-Based Karyotyping of Acute Promyelocytic Leukemia
Gómez-Seguí I; (...); Sanz MA
Article. 10.1371/journal.pone.0100245. 2014
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial.
Puig N; (...); Mateos MV
Article. 10.3324/haematol.2024.285742. 2024
Sister chromatid exchange, (SCE), High-Frequency Cells (HFCs) and SCE distribution patterns in peripheral blood lymphocytes of Spanish adult smokers compared to non-smokers
Sebastià N; (...); Montoro A
Article. 10.1016/j.fct.2014.01.011. 2014
SJOGREN-LARSSON SYNDROME IN TWO SISTERS WITH AN INTRONIC VARIANT OF ALDH3A2 GENE: CLINICAL FINDINGS
Fernandez, F.; (...); Cervera, J.
Meeting Abstract. 2019
Somatic Genetic and Epigenetic Architecture of Myelodysplastic Syndromes Arising from GATA2 Deficiency
Loyola, Victor Bengt Pastor; (...); Wlodarski, Marcin W.
Article. 2015
Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Palomo L; (...); Such E
Article. 10.1111/bjh.16175. 2020
STUDY OF PRE-EXISTING MUTATIONS IN HEMATOPOYETIC CELLS OF THE BONE MEDULA IN PATIENTS WITH MYELOID NEOPLASIAS RELATED TO THERAPY
Ibanez, M; (...); Sanz, G
Meeting Abstract. 2017
STUDY OF THE CLINICAL RELEVANCE AND GENOMIC PROFILE OF MINIMAL RESIDUAL MULTIPLE MYELOMA DISEASE IN PATIENTS WITH STANDARD RISK AND HIGH CYTOGENETIC RISK
Goicoechea, I; (...); Paiva, B.
Meeting Abstract. 2019
Study of the S427G polymorphism and of MYBL2 variants in patients with acute myeloid leukemia
Dolz S; (...); Barragán E
Article. 10.3109/10428194.2015.1049167. 2016
STUDY OF TRANSCRIPTIONAL DIFFERENCES BETWEEN THE IDH2 R140 AND R172 MUTATIONS BY MEANS OF MODELING IN THE ORGANISM CAENORHABDITIS ELEGANS
Gonzalez, Romero Elisa; (...); Cervera, Jose Vicente
Meeting Abstract. 2020
t(1;19)(q23;p13) TCF3-PBX1 May Not Be an Intermediate-Risk Subtype in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Patients Treated With MRD-Oriented Protocols from the PETHEMA Group
Ribera, J; (...); Ribera, JM
Meeting Abstract. 2021
T-cell Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.01.016. 2023
The Clinical Spectrum, Diagnosis, and Management of GATA2 Deficiency.
Santiago, Marta; (...); Cervera, Jose
Article. 10.3390/cancers15051590. 2023
The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS
Xicoy, Blanca; (...); Sanz, Guillermo
Letter. 10.1016/j.leukres.2018.05.003. 2018
The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial
Mosquera Orgueira, Adrian; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2023-180482. 2023
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.
Medina-Herrera A; (...); Garcia-Sanz R
Article. 10.1038/s41408-024-01053-3. 2024
The modular network structure of the mutational landscape of Acute Myeloid Leukemia
Ibanez, M; (...); Cervera, J
Article. 10.1371/journal.pone.0202926. 2018
THE MODULAR NETWORK STRUCTURE OF THE MUTATIONAL LANDSCAPE OF ACUTE MYELOID LEUKEMIA
Ibanez, M.; (...); Cervera, J.
Article. 2015
The Mutational Landscape of Acute Promyelocytic Leukemia Reveals an Interacting Network of Co-Occurrences and Recurrent Mutations
Ibáñez, M; (...); Cervera, J.
Article. 10.1371/journal.pone.0148346. 2016
The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis
Hernandez-Sanchez, Alberto; (...); Hernandez-Boluda, Juan Carlos
Letter. 10.1002/ajh.27203. 2024
The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
McGraw KL; (...); List AF
Article. 10.1038/bcj.2015.11. 2015
The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients
Paiva, Bruno; (...); San Miguel, Jesus
Meeting Abstract. 2015
The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies
Strebel, Johanna A. Kremer Hovinga; (...); Scully, Marie
Meeting Abstract. 10.1182/blood-2022-156306. 2022
The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients.
Villar, Sara; (...); Montesinos, Pau
Article. 10.3389/fonc.2022.1054458. 2022
Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain
Boluda, B; (...); Montesinos, P
Article. 10.1007/s41669-018-0098-8. 2019
TP53 ALLELIC STATE DID NOT INFLUENCE THE PROGNOSIS IN MYELODYSPLASTIC SYNDROMES (MDS) WITH 5Q DELETION
Montoro, M. J.; (...); Valcarcel, D.
Meeting Abstract. 10.1016/j.leukres.2023.107187. 2023
TP53 Allelic State in Myelodysplastic Syndromes with 5q Deletion
Montoro Gomez, Maria Julia; (...); Valcarcel, David
Meeting Abstract. 10.1182/blood-2022-165257. 2022
TP53 Gene allelic State in Myelodysplastic Syndromes (MDS) with Isolated 5q Deletion
Montoro, Julia; (...); Valcarcel, David
Meeting Abstract. 10.1182/blood-2023-179171. 2023
TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes
Bernard, Elsa; (...); Papaemmanuil, Elli
Meeting Abstract. 10.1182/blood-2019-129392. 2019
Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
Patricia Simoes, Catia; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2022-163159. 2022
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
Simoes, Catia; (...); Montesinos, Pau
Letter. 10.1111/bjh.18815. 2023
TRANSCRIPTOMICAL ANALYSIS AND MODELING IN C.ELEGANS OF THE IDH2 R140 R172 MUTATION
Gonzalez-Romero, E.; (...); Cervera-Zamora, J., V
Meeting Abstract. 2019
Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution.
Solves, Pilar; (...); Sanz, Jaime
Article. 10.3390/jcm12103467. 2023
Transfusion of ABO non-identical platelets does not influence the clinical outcome of patients undergoing autologous haematopoietic stem cell transplantation
Article. 10.2450/2015.0195-14. 2015
TRANSLOCATIONS IN THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: REVIEW OF 69 PATIENTS FROM THE SPANISH SMD GROUP DATABASE WITH AN EVALUABLE KARYOTYPE
Grau, Javier; (...); Granada, Isabel
Meeting Abstract. 2020
UBA1 Mutations Identify a Rare but Distinct Subtype of Myelodysplastic Syndromes
Sirenko, Maria; (...); Papaemmanuil, Elli
Meeting Abstract. 10.1182/blood-2023-182949. 2023
USE OF CRISPR/CAS9 TECHNOLOGY TO MODIFY THE IDH2 GENE IN BOTH IN-VIVO AND IN-VITRO MODELS
Gonzalez Romero, E.; (...); Cervera, J., V
Meeting Abstract. 2018
Use of optical genome mapping in the cytogenetic diagnosis of multiple myeloma
de la Rubia, Javier; (...); Such, Esperanza
Meeting Abstract. 2023
Utility of Optical Genome Mapping for Accurate Detection and Fine-Mapping of Structural Variants in Elusive Rare Diseases
Orellana, Carmen; (...); Martinez, Francisco
Article. 10.3390/ijms26031244. 2025
VALIDATION OF A NEW MASSIVE SEQUENCING TECHNIQUE FOR MOLECULAR DIAGNOSIS OF ACUTE MYELOBLASTIC LEUKEMIA
Llop Garcia, M.; (...); Barragan Gonzalez, E.
Meeting Abstract. 2015
Validation of a Next-Generation Sequencing Panel for AML Routine Diagnosis
Alonso, Carmen M.; (...); Barragan, Eva
Article. 2015
VALIDATION OF A PANEL OF GENES BY MASSIVE SEQUENCING FOR THE SCREENING OF GERMINAL MUTATIONS IN GENES ASSOCIATED WITH HEREDITARY MYELOID NEOPLASMS
Ibanez, M.; (...); Cervera, J., V
Meeting Abstract. 2019
VALIDATION OF DIFFERENT SYSTEMS OF STRATIFICATION OF PROGNOSIS OF SMD IN AN INDEPENDENT SERIES
Collado Jose, Esteban; (...); Sanz, Guillermo
Meeting Abstract. 2016
VALIDATION OF FREQUENT SPLICING EVENTS IN ACUTE MYELOID LEUKEMIA WITH POTENTIAL TO GENERATE NEOANTIGENS
Beatriz, Fernandez-Blanco; (...); Jose Vicente, Cervera Zamora
Meeting Abstract. 2021
Validation of the IMWG standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?
Jimenez Ubieto, Ana; (...); Lahuerta, Juan-Jose
Article. 10.1182/blood.2021012319. 2021
Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy
Mugoni, V; (...); Pandolfi, PP
Article. 10.1038/s41422-019-0162-7. 2019
What Is the Frequency of Transplant-Eligible Multiple Myeloma Patients Being Cured? the Impact of an MGUS-like Signature at Diagnosis and MRD-Negativity
Paiva, Bruno; (...); Jose Lahuerta, Juan
Meeting Abstract. 2015
WHOLE GENE SEQUENCING FOR THE IDENTIFICATION OF SPLICING MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
Mireya, Morote-Faubel; (...); Jose, Cervera
Meeting Abstract. 2021
WORKING SYSTEM DOCUMENTATION OF PROCEDURES AND INSTRUCTIONS FOR USE IN THE HEMATOLOGY DIAGNOSIS UNIT
Montalt, M.; (...); Sanz, M. A.
Meeting Abstract. 2015
WT1 isoform expression pattern in acute myeloid leukemia.
Article. 10.1016/j.leukres.2013.10.009. 2013
Zoledronic acid as compared with observation in multiple myeioma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial
Garcia-Sanz, R; (...); Mateos, MV
Article. 10.3324/haematol.2015.128439. 2015